Plato Investment Management Ltd Invests $635,000 in United Therapeutics Corporation $UTHR

Plato Investment Management Ltd bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,179 shares of the biotechnology company’s stock, valued at approximately $635,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Torren Management LLC acquired a new stake in United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management raised its position in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC lifted its stake in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its stake in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics during the fourth quarter worth about $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Up 1.9%

NASDAQ:UTHR opened at $518.27 on Wednesday. The business’s 50 day moving average is $534.53 and its two-hundred day moving average is $536.74. United Therapeutics Corporation has a 52 week low of $302.19 and a 52 week high of $609.35. The company has a market cap of $22.23 billion, a PE ratio of 18.54, a P/E/G ratio of 1.69 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the previous year, the company posted $6.41 earnings per share. The firm’s revenue was down 1.9% on a year-over-year basis. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of recent research reports. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Royal Bank Of Canada reduced their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. JPMorgan Chase & Co. upped their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research note on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $646.00.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total value of $5,202,295.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,185,323.93. The trade was a 19.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $564.11, for a total transaction of $5,641,100.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,648,140.36. This represents a 34.63% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 452,575 shares of company stock worth $245,684,184. Insiders own 8.60% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.